As an FDA-approved drug with documented pharmacokinetic and safety profiles in humans, and having potent inhibitory effects in multiple sites of the PI3K/ATK/mTOR axis in human lung cancer cells, auranofin is likely for rapid clinical translation of its new application for lung cancer therapy. Here, MTOR is linked to lung carcinoma.